Review
66 Enghard P, Zickler D, Sonnemann J, et al . Imlifidase as novel treatment strategy in anti-neutrophil cytoplasmic antibody-induced pulmonary-renal syndrome. Kidney Int 2021;100:1344–5. 67 Xiao H, Dairaghi DJ, Powers JP, et al . C5A receptor (CD88) blockade protects against MPO-ANCA GN. J Am Soc Nephrol 2014;25:225–31. 68 Jayne DRW, Bruchfeld AN, Harper L, et al . Randomized trial of C5a receptor inhibitor Avacopan in ANCA-associated vasculitis. J Am Soc Nephrol 2017;28:2756–67. 69 Jayne DRW, Merkel PA, Schall TJ, et al . Avacopan for the treatment of ANCA- associated vasculitis. N Engl J Med 2021;384:599–609. 70 Dick J, Gan P-Y, Ford SL, et al . C5A receptor 1 promotes autoimmunity, neutrophil dysfunction and injury in experimental anti-myeloperoxidase glomerulonephritis. Kidney Int 2018;93:615–25. 71 Stewart BJ, Ferdinand JR, Young MD, et al . Spatiotemporal immune zonation of the human kidney. Science 2019;365:1461–6.
72 Hočevar A, Tomšič M, Jurčić V, et al . Predicting gastrointestinal and renal involvement in adult IgA vasculitis. Arthritis Res Ther 2019;21:302. 73 Gomes RC, Silva MF, Kozu K, et al . Features of 847 childhood-onset systemic lupus erythematosus patients in three age groups at diagnosis: a Brazilian multicenter study. Arthritis Care Res 2016;68:1736–41. 74 Alamoudi OSB, Attar SM. Pulmonary manifestations in systemic lupus erythematosus: association with disease activity. Respirology 2015;20:474–80. 75 Kusyairi KA, Gendeh BS, Sakthiswary R, et al . The spectrum of nasal involvement in systemic lupus erythematosus and its association with the disease activity. Lupus 2016;25:520–4. 76 Frittoli RB, Vivaldo JF, Costallat LTL, et al . Gastrointestinal involvement in systemic lupus erythematosus: a systematic review. J Transl Autoimmun 2021;4:100106. 77 Retamozo S, Brito-Zerón P, Bosch X, et al . Cryoglobulinemic disease. Oncology 2013;27:1098–105.
Kronbichler A, et al . Ann Rheum Dis 2023; 82 :585–593. doi:10.1136/annrheumdis-2022-222495
593
Powered by FlippingBook